Volt PFA Catheter, Sensor Enabled
ABBOTT MEDICAL · Decision date Oct 8, 2026
What did the FDA decide?
FDA posted a 30-Day Notice for supplement S009 to PMA P250022 for the Volt PFA Catheter, Sensor Enabled, from Abbott Medical. The decision date is October 8, 2026, with decision code OK30. The stated purpose is minor dimensional tolerance changes on a catheter component.
The supplement type is a process change involving manufacturer, sterilizer, packager, or supplier. The device category is a percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation. The source statement does not specify which component changed, the magnitude of tolerance adjustment, or any associated testing. A supplement is not a new approval of the whole system.
FDA approval order statement
for minor dimensional tolerance changes on catheter component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 8, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250022/S009
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- QZI
- Decision code
- OK30
- Decision date
- Oct 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Abbott Medical
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250022. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250022 · Original PMA
Volt PFA System
P250022/S009 received
Application receipt date recorded by FDA.
P250022/S012 · Related supplement
VOLT PFA CATHETER, SENSOR ENABLED
P250022/S009 · FDA decision
30-Day Notice
P250022/S002 · Related supplement
Volt PFA System
Timeline entries are records held by MedtechLedger for P250022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Volt PFA SystemP250022 | ABBOTT MEDICAL | PMA approval | Dec 19, 2025 | FDA |
VOLT PFA CATHETER, SENSOR ENABLEDP250022/S012 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Sphere-9 Catheter and Affera Ablation SystemP240013/S028 | Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 5050 Nathan Ln. N., Plymouth, MN, 55442
Sources and methodology
- Original FDA record: P250022/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
